EGRX Eagle Pharmaceuticals Inc.

Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023

Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023

WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens.

Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:

Date

Time

Toll free (U.S.)

International

Thursday, November 9, 2023

8:30 a.m. ET

800-343-4136

203-518-9843
  
Webcast (live and replay), under the “Investor Relations” section
  

A replay of the conference call will be available for two weeks after the call's completion by dialing 888-562-0859 (U.S.) or 402-220-7342 (International) and entering conference call ID EGRXQ323. The webcast will be archived for 30 days at the aforementioned URL.

About Eagle Pharmaceuticals, Inc. 

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at .

Contact:

Investor Relations for Eagle Pharmaceuticals, Inc:

Lisa M. Wilson

T: 212-452-2793

E:



EN
08/11/2023

Underlying

EGRXEagle Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eagle Pharmaceuticals Inc.

 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BEND...

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockhol...

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in ful...

March 21, 2025 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financi...

Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the appointment of Christopher Krawtschuk as Chief Financial Officer (“CFO”) of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company’s board of directors. “Chris is a talented finance executive with deep exp...

November 12, 2024 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan

Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights agreement (the “Rights Plan”), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company’s stockholders to have the opportunity to realize the long-term value of ...

October 31, 2024 1 EN
 PRESS RELEASE
Free
EGRX Eagle Pharmaceu...

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from...

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an...

August 27, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch